CAMP4 Therapeutics Corporation
CAMPNASDAQHealthcare● Active
$4.09
$-0.02(-0.49%)
Market Cap$86872512
P/E Ratio—
52W High$7.75
52W Low$1.305
CAMP4 Therapeutics Corporation (CAMP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CAMP · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.32
Est. -$0.21 · -52.4%
Revenue
$0.00B
Est. $0.00B · +15.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
CAMP reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.52
Rev. $3.34B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.52
Rev. Est.$3.34B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.24 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.21 | -$0.32 | -52.4% | $0.00B | $0.00B | +15.7% |
| ▼ Q1 FY2026 | Mar 5, 2026 | -$0.31 | -$0.87 | -180.7% | $0.00B | $0.00B | -36.9% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.47 | -$0.55 | -17.0% | $0.00B | $0.00B | +83.5% |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.67 | -$0.62 | +7.5% | $0.00B | $0.00B | +1069.5% |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.70 | -$0.62 | +11.4% | $0.00B | $0.00B | +104.2% |
| ▼ Q1 FY2025 | Mar 27, 2025 | -$0.91 | -$2.83 | -211.0% | $0.00B | $0.00B | +1856.2% |
| ▼ Q4 FY2024 | Nov 21, 2024 | -$1.07 | -$24.19 | -2153.7% | — | $0.00B | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.24
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$0.32
EPS Est.
-$0.21
EPS Surpr.
-52.4%
Revenue
$0.00B
Q1 FY2026
Mar 5, 2026Miss
EPS Actual
-$0.87
EPS Est.
-$0.31
EPS Surpr.
-180.7%
Revenue
$0.00B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.55
EPS Est.
-$0.47
EPS Surpr.
-17.0%
Revenue
$0.00B
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.62
EPS Est.
-$0.67
EPS Surpr.
+7.5%
Revenue
$0.00B
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.62
EPS Est.
-$0.70
EPS Surpr.
+11.4%
Revenue
$0.00B
Q1 FY2025
Mar 27, 2025Miss
EPS Actual
-$2.83
EPS Est.
-$0.91
EPS Surpr.
-211.0%
Revenue
$0.00B
Q4 FY2024
Nov 21, 2024Miss
EPS Actual
-$24.19
EPS Est.
-$1.07
EPS Surpr.
-2153.7%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.39 | $-0.23 | $-0.07 | 1 |
| Q3 FY2028 | $-0.39 | $-0.23 | $-0.07 | 1 |
| Q2 FY2028 | $-0.38 | $-0.23 | $-0.07 | 1 |
| Q1 FY2028 | $-0.39 | $-0.23 | $-0.07 | 1 |
| Q4 FY2027 | $-0.35 | $-0.21 | $-0.06 | 1 |
| Q3 FY2027 | $-0.32 | $-0.19 | $-0.05 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -52.4% | $4.06 | $4.34 | +6.90% |
| ▼ Q1 FY2026 | Mar 5, 2026 | -180.7% | $4.08 | $4.59 | +12.50% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -17.0% | $4.16 | $4.45 | +6.97% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +7.5% | $1.46 | $1.55 | +6.16% |
| ▲ Q2 FY2025 | May 13, 2025 | +11.4% | $2.10 | $2.02 | -3.81% |
| ▼ Q1 FY2025 | Mar 27, 2025 | -211.0% | $4.92 | $4.42 | -10.16% |
| ▼ Q4 FY2024 | Nov 21, 2024 | -2153.7% | $5.33 | $5.78 | +8.44% |
| ▼ Q3 FY2024 | Jul 8, 2024 | -5613.0% | No price data | $10.72 | — |
Q2 FY2026+6.90%
Report Date
May 7, 2026
EPS Beat/Miss
-52.4%
Price Before
$4.06
Price After
$4.34
Q1 FY2026+12.50%
Report Date
Mar 5, 2026
EPS Beat/Miss
-180.7%
Price Before
$4.08
Price After
$4.59
Q4 FY2025+6.97%
Report Date
Nov 6, 2025
EPS Beat/Miss
-17.0%
Price Before
$4.16
Price After
$4.45
Q3 FY2025+6.16%
Report Date
Aug 14, 2025
EPS Beat/Miss
+7.5%
Price Before
$1.46
Price After
$1.55
Q2 FY2025-3.81%
Report Date
May 13, 2025
EPS Beat/Miss
+11.4%
Price Before
$2.10
Price After
$2.02
Q1 FY2025-10.16%
Report Date
Mar 27, 2025
EPS Beat/Miss
-211.0%
Price Before
$4.92
Price After
$4.42
Q4 FY2024+8.44%
Report Date
Nov 21, 2024
EPS Beat/Miss
-2153.7%
Price Before
$5.33
Price After
$5.78
Q3 FY2024—
Report Date
Jul 8, 2024
EPS Beat/Miss
-5613.0%
Price Before
—
Price After
$10.72
Avg Beat Reaction+1.18%
Avg Miss Reaction+4.93%
Beat Rate2 / 8 quarters
Largest Move+12.50% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CAMP ends December
CAMP4 Therapeutics Corporation (CAMP) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.32 — missing the analyst consensus of $-0.21 by -52.4%. The next CAMP earnings date is expected around September 1, 2026.
Each quarter, investors track CAMP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CAMP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CAMP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CAMP earnings · 5 questionsCAMP4 Therapeutics Corporation's next earnings report is expected around September 1, 2026. CAMP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CAMP historically reports after market close (AMC).
CAMP earnings datewhen is CAMP earningsCAMP next earnings datewhen does CAMP report earningsCAMP earnings calendar
▸ Source: FMP · CAMP4 Therapeutics Corporation SEC filings · US GAAP · CAMP4 Therapeutics Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026